AIIMS Delhi to start paediatric trials for Covaxin: Report
The paediatric trials for Covaxin started in AIIMS Patna on Tuesday after Bharat Biotech's COVID vaccine received the Drugs Controller General of India (DCGI) nod to conduct clinical trials on children on May 11.
New Delhi: After All India Institute of Medical Sciences (AIIMS), Patna, now AIIMS Delhi is also planning to start the Paediatric clinical trials of the indigenous Bharat Biotech's COVID-19 vaccine "Covaxin" in few days, sources said on Thursday.
The paediatric trials for Covaxin started in AIIMS Patna on Tuesday after Bharat Biotech's COVID-19 vaccine received the Drugs Controller General of India (DCGI) nod to conduct clinical trials on children on May 11.
"AIIMS Patna has started trials in the age of 12-18 years, we have started clinical trials of Covaxin after registration for this age only," said Dr Prabhat Kumar Singh, Director, AIIMS, Patna.
"After these trials, the age group will be 6-12 years and then 2-6 years but now we have started trails in the age group of 12-18 years," he added.
VK Paul, Member (Health), Niti Aayog had earlier said, "Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years."
India started the world's largest vaccination drive on January 16 this year in a phased manner with healthcare workers (HCWs) getting inoculated first. The vaccination of frontline workers (FLWs) started on February 2.
The next phase of Covid-19 vaccination commenced from March 1 for those over 60 years of age and for people aged 45 and above with specified co-morbid conditions. India launched vaccination for all people aged more than 45 from April 1.
The third phase of the vaccination started on May 1 for the beneficiary aged between 18-44.
India has three COVID-19 vaccines - Bharat Biotech's Covaxin, Serum Institute's Covishield, and Russia's Sputnik V. Covaxin and Covishield are being manufactured in India.
Also Read: Bharat Biotech, Gujarat Covid Vaccine Consortium ink pact for Covaxin drug substance
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.